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Edited by Bernd HelmsAbstract Sphingolipids are known to play important roles in
the regulation of cell proliferation, response to chemotherapeutic
agents, and/or prevention of cancer. Recently, signiﬁcant pro-
gress has been made in the identiﬁcation of the enzymes and their
biochemical functions involved in sphingolipid metabolism. In
addition, development of new techniques for the quantitative
analysis of sphingolipids at their physiological levels has facili-
tated studies to examine distinct functions of these bioactive
sphingolipids in cancer pathogenesis and therapy. This review
will focus on the recent developments regarding the roles of bio-
active sphingolipids in the regulation of cell growth/proliferation,
and anti-cancer therapeutics.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Chemoprevention1. Introduction
Sphingolipids are a family of membrane lipids that have
structural roles in the regulation of the ﬂuidity and the sub-
domain structure of the lipid bilayers [1]. In addition, bioactive
sphingolipids such as ceramide, glycosylceramide (GlcCer),
sphingosine, and sphingosine-1-phosphate (S1P) also act as
bioeﬀector molecules, which play important roles in various
aspects of cancer biology including apoptosis, cell prolifera-
tion, cell migration, senescence, and inﬂammation [1,2]. These
sphingolipid-regulated processes, in turn, are crucial in cancer
development and progression, and inﬂuence the eﬃcacy of
anti-cancer therapeutics [1–6].2. Involvement of sphingolipids in the regulation of cancer
growth and pathogenesis
Ceramide is central to sphingolipid metabolism (Figs. 1 and
2) [7,8], exerting bioeﬀector functions for anti-proliferative
responses such as apoptosis, growth arrest, and/or senescence
(Fig. 3); thus, it is gaining recognition as a tumor suppressor
lipid [1,2]. The cellular levels of long-chain endogenous cera-*Fax: +1 843 792 8568.
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doi:10.1016/j.febslet.2006.08.052mides increase in response to stress-causing agonists, such as
UV-irradiation, hyperthermia (heat-stress), or chemotherapeu-
tic agents [2–4], via the activation of de novo synthesis and/or
sphingomyelinases that hydrolyze sphingomyelin (SM)
(Fig. 1). Ceramide then mediates anti-proliferative pathways,
or inhibits pro-survival mechanisms, mainly by regulating
multiple signaling cascades controlled by protein phosphatase
1 and 2A (also known as CAPPs, ceramide-activated protein
phosphatases), kinases, or cathepsin D (Fig. 3) [1,2]. Down-
stream indirect targets of ceramide signaling include telomeres,
which rapidly shorten [9]; and human telomerase reverse trans-
criptase (hTERT) expression, which is modulated [10,11].
Telomerase elongates telomeres at the end of chromosomes,
and is involved in cellular immortalization and malignant
transformation when other oncogenic signals are present
[12]. Transcription of hTERT, the catalytic subunit of
telomerase, is inhibited by ceramide in c-Myc- and Sp1/Sp3-
dependent mechanisms via increased ubiquitination and
deacetylation, respectively [11,13]. Ceramide also activates
RB and p53-dependent cell death, and regulates the functions
of cyclin-dependent kinases and apoptosis-related proteins
such as Bcl-2, caspases, and proteases (Fig. 3) [14–17]. Cera-
mide also induces caspase-independent apoptosis [18].
On the other hand, S1P, a product of SK (Fig. 1), is consid-
ered to be a pro-survival lipid, because of its involvement in
malignant transformation, cancer proliferation, inﬂammation,
vasculorogenesis, and resistance to apoptotic cell death [19–
21]. Increased generation of S1P triggers signaling pathways
that mediate these pro-survival processes within the cell or
by engaging S1P receptors 1–5 (S1PR), a member of the family
of transmembrane hepta-helical G-protein-coupled receptors,
which are encoded by the endothelial diﬀerentiation genes
(EDG) in a paracrine or autocrine manner after being secreted
from the cell (Fig. 3) [22].
2.1. Roles of endogenous ceramide as a tumor suppressor lipid
Generation of endogenous ceramide in response to various
stress stimuli has long been associated with senescence, growth
arrest, or cell death [1,2]. In addition, enzymes involved in cer-
amide metabolism are also implicated in the regulation of can-
cer cell growth and/or survival. For example, human N-SMase
2 was reported to be a key regulator of cell growth and cell
cycle progression but not apoptosis [23]. On the other hand,
enzymes that attenuate ceramide levels, such as ceramidases
(CDases), glucosylceramide synthase (GCS), and SK1 exert
opposing eﬀects, leading to anti-apoptotic, pro-survival, and/
or resistance to chemotherapy in various cancer cells [24–26].blished by Elsevier B.V. All rights reserved.
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Fig. 1. Metabolism of sphingolipids. Ceramide can be formed de novo, involving serine palmitoyl transferase (SPT), (dihydro)ceramide synthase
(CerS, or Lass1-6), and dihydroceramide desaturase (DES), or via the hydrolysis of sphingomyelin (SM) by sphingomyelinases (SMases). Ceramide
can also be a precursor for the synthesis of SM catalyzed by SM synthase (SMS) and involving the hydrolysis of phosphatidylcholine (PC) to
diacylglycerol (DAG), cerebrosides such as glucosylceramide (GlcCer) by glucosylceramide synthase (GCS), or galactosylceramide, and ceramide-1-
phosphate (Cer-1-P) via ceramide kinase (CK). Hydrolysis of ceramide by ceramidases (CDases) releases sphingosine, which can be further converted
to sphingosine-1-phosphate (S-1-P) by sphingosine kinase (SK). S-1-P can be cleaved into ethanolamine and fatty aldehyde by S1P lyase.
Alternatively, dephosphorylation of Cer1P or S-1-P by their phosphatases (C1PP and S1PP, respectively) yields ceramide. Metabolism of
cerebrosides by cerebrosidase (CRS) also generates ceramide.
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pressor lipid, attenuation of ceramide in clinical samples corre-
lates inversely with the degree of malignant progression and
with the severity of prognosis of patients with malignant astro-
cytomas [27]. Similarly, the total content of ceramide was
decreased in ovarian tumors when compared to normal ovar-
ian tissues [28].
Recently, major genetic and biochemical advances have in-
creased our understanding of the metabolic and biological
functions of ceramide synthases (CerS) in the de novo path-
way. Previously, the yeast longevity assurance gene 1
(LAG1) and its homologue LAC1 were identiﬁed as key com-
ponents of CerS [29,30]. LAG1 is known to regulate life-
span/longevity in Saccharomyces cerevisiae, and its deletion
prolongs the yeast life-span [31]. A mouse homologue of
LAG1 (Lass1), also known as the upstream of growth and
diﬀerentiation factor 1 (UOG1) [32], was identiﬁed to specif-
ically regulate the synthesis of C18-ceramide [32,33], and this
was the ﬁrst case of high-degree of fatty acid speciﬁcity in the
generation of ceramide. The Lass [34] genes belong to a
large family of endoplasmic reticulum (ER) membrane-asso-
ciated proteins with conserved trans-membrane alpha-helices,
called the TRAM-Lag1p-CLN8 (TLC) domain, which is cru-
cial for the generation of ceramide [35]. There are six mam-
malian homologues of Lass proteins (Lass1–6), and all,
except Lass1, contain a homeobox transcription factor
HOX domain found at the N-terminal to the TLC domain[35,36]. The function for the HOX domain, however, is still
unknown.
More importantly, human Lass1 was shown to reconstitute
long-chain ceramide synthesis in LAG1-deleted mutants of
yeast [37]. Interestingly, in mammalian cells, each Lass protein
exerts speciﬁcity for the generation of distinct endogenous
ceramides with high fatty-acid chain length speciﬁcity
[32,33,38,39]. For example, Lass1 was shown to speciﬁcally
generate ceramide with an 18-carbon containing fatty acid
chain (C18-ceramide) [32,39], whereas Lass5-6 mainly gener-
ates C16-ceramides (Fig. 2) [41,42]. Indeed, Lass5 was shown
to be the bona ﬁde ceramide synthase for the generation of
C16-ceramide [40], whereas yeast LAG1 requires LAC1 and
Lip1 for ceramide synthesis [41].
The biological functions of these Lass-generated ceramides
in regulating cell growth and/or pathogenesis have been inves-
tigated. Defects in the Lass1-dependent generation of C18-cer-
amide were implicated in the pathogenesis and/or progression
of squamous cell carcinomas of the head and neck (HNSCC)
[42]. Speciﬁcally, it has been shown that the majority of
HNSCC tumors contained lower levels of C18-ceramide com-
pared to their normal counterparts, suggesting that defects in
the Lass1/C18-ceramide pathway might be important in
HNSCC tumor growth and/or progression [42]. Also, a role
for Lass1 in the regulation of growth and apoptosis of neuro-
nal ceroid lipofuscinosis, a hereditary childhood neurological
disorder, has been recently demonstrated [43], conﬁrming the
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Fig. 2. Roles of Lass1-6 in the generation of ceramide with distinct
fatty acid chain lengths. Ceramide is composed of a sphingosine base
(shown in red) and an amide-linked fatty acyl chain varying in length
from 14 to 26 carbons (C18-fatty acyl chain is shown in blue).
Ceramide then serves as the metabolic and structural precursor for
complex sphingolipids, which are composed of hydrophilic head
groups (shown in green), such as SM, C1P, and GlcCer, which itself is
the precursor for a variety of complex glycolipids and gangliosides, as
shown in Fig. 1. In previous studies, yeast longevity assurance gene 1
(LAG1) and its homologue LAC1 were identiﬁed as key components
of CerS of the de novo pathway, and six mammalian homologues of
the yeast LAG1 (re-named as Lass1-6) were identiﬁed. Interestingly, in
mammalian cells, each Lass protein exerts speciﬁcity for the generation
of endogenous ceramides with distinct fatty-acid chain lengths.
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Fig. 3. The biological roles of sphingolipids involved in the regulation
of cancer growth and therapy. Various stress stimuli can induce the
generation of endogenous ceramide mainly via the activation of the de
novo pathway, or hydrolysis of SM by SMases. Ceramide, then,
mediates anti-proliferative responses by regulating its down-stream
targets or signaling events, including cathepsin D, ceramide-activated
protein phosphatases (CAPP), and kinases such as the kinase
suppressor of RAS (KSR), MAPK, RAF-1, PKCf [133], or MEKK
(MAP/ERK kinase kinase). Down-stream indirect targets of ceramide
include RB, caspases, c-Myc, and telomerase. Alternately, conversion
of ceramide to GlcCer, S1P, or SM, which yields DAG as a byproduct,
results in drug-resistance, malignant transformation, cell proliferation,
migration, or blood vessel formation, all of which constitute pro-
survival phenotypes. Activation of S1P/S1PR signaling involves the
activation of COX-2, ERK, and NF-jB, or inhibiton of BAX and
caspases. Mechanisms also exist to induce the translocation of SK1
from the cytoplasm to the plasma membrane via TNF-a/TNFR1
signaling, leading to increased generation of S1P and intracellular S1P
signaling, such as the activation of NF-jB.
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ious biological disorders.
Interestingly, our recent data also demonstrated that the
levels of C16-ceramide are signiﬁcantly upregulated in HNSCC
tumors, compared to their normal adjacent tissues. Similarly,
C16-ceramide is greatly reduced upon mUOG1/Lass1 overex-
pression and increased generation of C18-ceramide in HNSCC
cells [42]. Also, high levels of C16-ceramide were observed in
Sarcoma 180 tumors grown inmice [44]. These data suggest that
endogenous ceramides with diﬀerent fatty acid chain lengths
might have distinct biological functions. For example, while
C18-ceramide induces anti-proliferative responses, C16-cera-
mide might exert pro-survival responses. These results are
surprising, because the role for increased C16-ceramide (in
response to various stimuli) in apoptosis via the de novo path-
way in Jurkat cells [45] and in pancreatic cancer cells [46] have
been previously demonstrated. The reason for such diﬀerent
functions for ceramides is unclear; however, speciﬁc down-
stream targets and/or sub-cellular localization/compartmental-
ization of these ceramides might be involved in their distinct
functions for the regulation of growth or apoptosis in diﬀerent
types of cancer cells or patho-physiological conditions.
These results also point to the importance of the use of LC/
MS [47–50], which can identify the levels of diﬀerent ceramide
species in a given sample, as a powerful tool for discovering the
roles for speciﬁc ceramide species (with diﬀerent fatty acid
chain length) in the regulation of cancer cell growth and/
or pathogenesis. Metabolomic proﬁling of sphingolipids in
human glioma cell lines showed that diﬀerent glioma cell lines
had unique amounts and types of sphingolipids, and the fatty
acyl chain distributions of sphingolipids were also diﬀerent
among these cell lines [51].Collectively, these data suggest that alterations of the levels
and/or types of endogenous ceramide with diﬀerent fatty acid
chain lengths via Lass proteins may play important and dis-
tinct roles in the regulation of tumor viability and/or progres-
sion, and responses to anti-cancer therapeutics.
2.2. Roles of S1P as a pro-survival and anti-apoptotic molecule
S1P, as opposed to ceramide, plays important roles in induc-
ing cell proliferation, transformation, anti-apoptosis, and cell
migration of various cell types [19–21]. Overexpression of
SK1, which signiﬁcantly induces the levels of S1P, in 3T3 cells
results in malignant transformation and tumor formation [52].
Increased S1P levels promote proliferation and survival in hu-
man glioma and breast cancer cells [53–55]. SK1/S1P/S1PR
signaling also has several speciﬁc eﬀects on the promotion of
vascular development, and angiogenesis via stimulation of
endothelial and smooth muscle cells [56–58]. On the other
hand, partial inhibition of SK1 expression results in apoptosis
in MCF-7 human breast cancer cells [59]. Decreased stability
of SK1 protein in response to tumor necrosis factor (TNF)-a
by the activation of cathepsin B has also been demonstrated
in MCF-7 cells [60].
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matory responses has been reported [61]. Pro-inﬂammatory
cytokine TNF-a is known to activate SK1, in a TRAF2-depen-
dent mechanism, resulting in the translocation of SK1 to the
plasma membrane, and increases the accumulation of S1P,
which then mediates the activation of NF-jB [62]. Moreover,
S1P induces overexpression of Cox-2, and production of pros-
taglandin E2 (PGE2) in L929 ﬁbrosarcoma and in A549 lung
adenocarcimona cells [63]. This function of S1P may play
key roles in the development of colon cancers, because Cox-
2 and PGE2 production are established key regulators of colon
cancer progression [64]. This has been recently examined, and
the data showed that SK-1 and Cox-2 expression are co-regu-
lated in rat model of colon carcinogenesis [65]. The overexpres-
sion of SK1 was also detected in the majority of tumors
obtained from patients with lung cancer [66]. These data sug-
gest that these tumors may accelerate the metabolism of cera-
mide and generate increased levels of S1P. Thus, modulation
of S1P levels increases apoptosis, or abolishes starvation-in-
duced autophagy, which leads to increased cell death [67].
An interesting role for S1P was revealed in studies employ-
ing the potent immunosuppressive agent FTY720 [68,69]. This
compound is phosphorylated in vivo to FTY720-P [70,71],
which then induces sequestration of lymphocytes in lymph tis-
sues by engaging S1PRs with high aﬃnity and speciﬁcity
[68,69]. These data implicate that S1P receptors play important
roles in immunosuppression. More importantly, antagonism of
S1PRs by FTY720 inhibits angiogenesis and tumor vasculari-
zation, which may provide a new approach for treatment of
cancers with altered angiogenesis [72]. Interestingly, FTY720
also inhibits S1P lyase activity [73], which is known to play
important roles in enhancing stress-induced ceramide genera-
tion and apoptosis upon its activation [74], and its inhibition
by FTY720 might present potential problems in cells whose
growth and/or proliferation is regulated by S1P lyase.
Taken together, these studies demonstrate that sphingolipids
play important biological functions in the regulation of cancer
growth and/or pathogenesis. Speciﬁcally, attenuation of the
levels of ceramide may result in increased tumor growth and/
or progression, whereas induction of the levels of the tumor
promoting lipid S1P would enhance immortalization, transfor-
mation, cell migration, and perhaps induce new blood vessel
formation along with induction of inﬂammation and anti-
immune cell functions.3. Implications of sphingolipid metabolism and signaling in
cancer therapy
Since ceramide mediates anti-proliferative responses whereas
S1P enhances tumor-promoting cell responses, strategies which
either mimic/antagonize these sphingolipids or modulate their
levels could provide novel modalities for improved cancer ther-
apy, enhanced drug action, reverse drug resistance, and protect
normal cells from cytotoxic side-eﬀects, creating possibilities
for chemoprevention.
3.1. Roles of ceramide metabolism, and ceramide analogues/
mimetics in anti-cancer therapeutics
The roles of ceramide in the regulation of cell growth and in
chemotherapy-induced cell death suggest novel therapeutic ap-
proaches based on elevating levels of endogenous ceramideand/or mimicking its actions. Treatment of human cancer cells
with chemotherapeutic agents, such as daunorubicin, vincris-
tine, or gemcitabine, usually results in the generation of cera-
mide via the de novo pathway, or activation of SMases [1,2].
Targeting enzymes of ceramide clearance appears to elevate
endogenous levels of ceramide, leading to increased cytotoxic
responses in various cancer cells [2–6]. Moreover, combining
the chemotherapeutic agent gemcitabine with SM synergisti-
cally inhibits pancreatic tumor growth in vivo [75]. The cyto-
toxic eﬀects of doxorubicin were also enhanced when used in
combination with SM in various human cancer cell lines [76].
Mechanistically, SM was shown to increase the cellular uptake
of doxorubicin via altering cell membrane permeability, lead-
ing to increased accumulation and bioavailability of the drug
in these cells [76].
In a complementary approach, analogues and mimetics of
ceramide such as C2- and C6-ceramides induce cell death in a
myriad of cancer types. Because of the poor solubility and bio-
availability of conventional exogenous ceramides, novel pyrid-
inium ceramides (Pyr-Cer) have been synthesized with greater
water solubility and cell-membrane permeability [77–80]. The
positive charge of the pyridinium ring in these structures per-
mits targeting and accumulation of these ceramide analogues
into negatively charged intracellular compartments, especially
the mitochondrion and nucleus. These properties might be
exploited for preferential targeting into tumor sites: studies
suggest that cancer cells acquire, in general, a more negative
charge in their sub-cellular structures (in mitochondria and/
or nuclei) [81]. The accumulation of L-t-C6-Pyr-Cer preferen-
tially in mitochondria-, and nuclei-enriched fractions was
established in several human cancer cells in vitro [77–79],
and this was consistent with the higher accumulation of the
compound in the HNSCC tumor site, compared to the liver
and intestines in vivo [80]. The accumulation of Pyr-Cer in
the mitochondria caused dramatic alterations in the structures
and functions of mitochondria, resulting in apoptotic cell
death [78,79]. L-t-C6-Pyr-Cer, alone or in combination with
gemcitabine, has been shown in vivo to modulate telomerase,
decrease telomere length, and inhibit HNSCC tumor growth
in SCID mice [80].
Other novel structural analogs of ceramide, such as C16-ser-
inol and (2S,3R)-(4E,6E)-2-octanoylamidooctadecadiene-1,3-
diol (4,6-diene-ceramide) induced apoptosis in neuroblastoma,
and breast cancer cells, respectively [82,83]. Other ceramide
analogs, 5R-OH-3E-C8-ceramide, adamantyl-ceramide and
benzene-C4-ceramide selectively inhibited the growth of drug-
resistant human breast cancer cell lines (SKBr3 and MCF-7/
Adr) [84].
In an alternative approach, delivery of exogenous ceramide
in pegylated liposomes, which are generally more eﬀective at
crossing the cell membrane, increased growth inhibitory eﬀects
in human breast cancer cells, via enhanced accumulation of
ceramide [85]. The liposomal delivery of exogenous natural
ceramide also resulted in the inhibition of phosphorylated
Akt and stimulated the activity of caspase-3/7 more eﬀectively
than non-liposomal ceramide [85]. In vivo therapeutic eﬃcacy
of the pegylated ceramide for the delivery of exogenous cera-
mide, which resulted in slower tumor growth in murine models
of breast cancer, was also demonstrated [86]. Encapsulated
vincristine in SM-liposomes, also called sphingosomes has im-
proved eﬃcacy as compared to the conventional drug in ani-
mal models of adult acute lymphocytic leukemia (ALL), and
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treatment of patients with recurrent and refractory adult
ALL [87].
These preliminary approaches point to the feasibility of
developing more active and perhaps more selective analogs
of ceramide, which can be tested in clinical trials for the treat-
ment of patients with cancer. They also raise the possibility
that several enzymes of ceramide clearance (SM synthases,
CDases, and GCS) may serve as novel therapeutic targets. In
fact, an inhibitor of acid-CDase B13 induces apoptosis, and
inhibits tumor growth in prostate cancer xenografts [88].
3.2. Targeting the SK1/S1P pathway as an anti-cancer
therapeutic
Modulation of S1P biosynthesis provides another therapeu-
tic modality for the treatment of cancers. Conversely, exoge-
nous S1P treatment exerts a protective role against cell death
in normal (non-cancerous) human cells. S1P suppressed che-
motherapy-induced apoptosis in the ovary [89], and also
blocked male germ cell apoptosis in the human testis [90]. Re-
cently identiﬁed inhibitors of SK1 have been shown to inhibit
the cancer cell proliferation and tumor growth in situ and in
animal models [91]. There are also novel S1PR1 and S1PR3
antagonists [92], and inhibition of these receptors with these
compounds may inhibit cancer cell growth. This possibility,
however, has not been reported. Thus, it is interesting to
hypothesize that inhibition of SK1 may enhance the treatment
of cancer cells, whereas selective elevation of S1P levels in
normal cells may provide protection against toxicity during
therapy.
Another novel approach to cancer therapeutics employs a
monoclonal antibody that binds S1P with high aﬃnity and
speciﬁcity [93]. The anti-S1P monoclonal antibody (anti-S1P
mAb) signiﬁcantly reduced tumor progression via anti-angio-
genic and antitumorigenic eﬀects in various murine xenograft
and allograft models [93]. The anti-S1P mAb also prevented
S1P-induced cell proliferation, release of pro-angiogenic cyto-
kines, and protection of tumor cells from apoptosis by S1P
[93]. Thus, these data strongly suggest that S1P may present
an important target for anti-cancer therapeutics.4. Involvement of sphingolipids in drug resistance
Tumor cells often acquire resistance to chemotherapy, a
major obstacle to successful clinical treatments. Interestingly,
a relationship between the changes in the sphingolipid metab-
olism and development of drug resistance in human cancer
cells has been documented [94–97].
4.1. Roles of ceramide metabolism in the development of drug
resistance
Attenuation of ceramide levels by glucosylceramide synthase
(GCS), an enzyme that converts ceramide to glucosylceramide
(GlcCer) (Fig. 1), has been implicated in the development drug
resistance in various cancer cell types, especially in breast can-
cer cells (Fig. 3) [94,98]. Although, the role of GCS in the
development of drug-resistance has been challenged in some
cancer models [99,100], a mechanistic link between GCS and
P-glycoprotein (P-gp), an ABC transporter implicated in drug
resistance, has been recently revealed [101]. The data demon-strated that downregulation of GCS expression by small inter-
fering RNA (siRNA) results in a signiﬁcant inhibition in the
expression of MDR1, a gene that encodes for P-gp, and
reverses drug resistance in drug resistant MCF-7-AdrR cells
[101]. In fact, SDZ PSC 833, which is a known blocker of
P-gp, has been shown to also inhibit GCS, and alter GlcCer
levels [102]. Interestingly, several members of the ABC trans-
porter family are implicated in the translocation of phospho-
lipids and sphingolipids across the lipid bilayer, and P-gp
has been proposed as a speciﬁc transporter for glucosylcera-
mide that translocates this molecule across the Golgi to deliver
it for the synthesis of neutral glycosphingolipids [103]. In
support of this hypothesis, increased accumulation of GlcCer
has been detected in various P-gp overexpressing cells [104].
Thus, P-gp and GCS appears to function in the same pathway
of ceramide/glucosylceramide metabolism, and this may pro-
vide an important link for the function of GCS in drug resis-
tance.
Interestingly, ABC transporters were found to accumulate in
non-caveolar and detergent insoluble glycosphingolipids-en-
riched membrane domains (DIGs) in multi-drug resistant can-
cer cells [105]. The sphingolipid content of DIGs in drug
resistant cells is diﬀerent, and contains sphingolipids with spe-
ciﬁc fatty acids, such as C24:1, when compared to sensitive
cells [106]. Thus, the content of sphingolipids in DIGs might
be an important determinant for the localization of ABC
transporters in membranes, which regulates drug uptake/eﬄux
and resistance.
4.2. Roles of SK-1/S1P in drug resistance
SK-1 appears to alter the ceramide/S1P balance, eﬀectively
regulating drug-induced apoptosis, and serving as a chemo-
therapy sensor both in culture and in animal models of pros-
tate adenocarcinoma [107]. In parallel with these data,
increasing the expression of SK-1 reduced the sensitivity of
A-375 melanoma cells to Fas- and ceramide-mediated apopto-
sis that could be reversed by inhibition of SK-1 expression [25].
More importantly, in unbiased molecular genetic studies con-
ducted using the model organism Dictyostelium discoideum,
modulation of SK or S1P lyase has been suggested to contrib-
ute to altered sensitivity to cisplatin [108]. The role of S1P lyase
in increased sensitivity to this drug in a p38-, and to lesser
extent, c-Jun NH2-terminal kinase (mitogen-activated protein
kinases)-dependent manner, was conﬁrmed in human A549
lung cancer and HEK293 cells [109]. Also, high expression lev-
els of SK1 and S1PRs were detected in camptothecin (CPT)-
resistant PC3 prostate cancer cells [110]. Speciﬁcally, inhibition
of SK1 expression or S1PR signaling signiﬁcantly inhibited
PC3 cell growth, and treatment of these cells with CPT in-
duced upregulation of SK1/S1PR signaling [110].
Thus, these data implicate that SK1/S1PRs protect cancer
cells from chemotherapy-induced apoptosis, and that changes
in the sphingolipid metabolism play functional roles in confer-
ring drug resistance.
Taken together, strategies that manipulate the metabolism
of sphingolipids, resulting in enhanced ceramide levels in can-
cer cells, have been developed as novel approaches for cancer
chemotherapy [2–5]. For example, combinations of fenretinide
(4-HPR), which is known to elevate ceramide [111] and (dihy-
dro)ceramide levels [43], with the inhibitors of GCS or SK,
such as PPMP (1-phenyl-2-palmitoylamino-3-morpholino-1-
propanol) or saﬁngol (L-thereo-dihydrosphingosine), were
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synergistically [112,113]. In fact, the clinical eﬃcacy of such
combinations mentioned above is currently being tested in hu-
man clinical trials [5].5. Roles of sphingolipids in cancer preventive strategies
There have been intriguing possibilities for the roles of
sphingolipids in chemoprevention [114]. There are at least
three distinct lines of investigation that demonstrated the link
between sphingolipids and chemoprevention. First, feeding
studies in animal models revealed the preventive actions of
dietary sphingolipids in various models of cancer. Speciﬁc
and controlled administration of SM in the diet of mice sup-
pressed the formation of chemically-induced colon cancer
tumors and aberrant colonic crypts by decreasing the rate
of cell proliferation and increasing apoptosis [115]. Feeding
diets supplemented with ceramide, sphingomyelin, glucosyl-
ceramide, lactosylceramide, or ganglioside G(D3) to C57B1/
6J(Min/+) mice with a truncated APC gene product, reduced
the number of tumors in all regions of the intestine [115,116].
Interestingly, the major digestion product of complex sphin-
golipids was identiﬁed as sphingosine, which induced cell
death in human colon cancer cell lines in culture. Mechanisti-
cally, prevention of colon cancer by dietary sphingolipids was
linked to their function in bypassing or correcting defects in
the APC/beta catenin regulatory pathway [115,116]. These
results, therefore, raise the possibility that modulation of
dietary sphingolipids may contribute to the prevention of
colon carcinogenesis.
A second line of investigation connects the action of resvera-
trol, a chemopreventive agent found at high levels in red wine,
to ceramide, such that apoptosis induced by resveratrol in
breast cancer cells depended on de novo-generated ceramide
[117,118]. Whether the roles of resveratrol in the generation
of ceramide and induction of apoptosis would carry over to
in vivo models of breast cancers needs to be determined.
In another set of experiments, the role of S1P in the induc-
tion of Cox2 expression, and in the production of prostaglan-
dins [63], coupled with ﬁndings of increased levels of SK1 in
colon cancer, and colon carcinogenesis [65], raises the possibil-
ity of utilizing SK1 as a novel target for chemoprevention.
Cox2 itself has emerged as a signiﬁcant target for chemopre-
vention of colon cancer, and this may extend to other cancer
types. By acting upstream of Cox2, overexpression of SK1
may present an exploitable defect in the pathogenesis of colon
cancer, aﬀording a target for chemoprevention of these can-
cers.6. Future perspectives
There is increasing evidence that altered regulation of cera-
mide levels and expression of enzymes of sphingolipid meta-
bolism might play important roles in the abnormal growth
of various cancers, and this is consistent with the emerging
tumor-suppressor functions of ceramide.
In addition to classical chemotherapeutic agents, other fac-
tors with potential anti-tumor functions can stimulate ceramide
generation. For example, Delta(9)-tetrahydrocannabinol exertsapoptosis in Jurkat cells via the CB(2) cannabinoid receptor
by activation of ceramide generation de novo, which plays a role
in the mitochondrial intrinsic pathway [119]. Similarly, treat-
ment of prostate and lung cancer cells with gamma-tocopherol
(gammaT), themain dietary form of vitamin E, inhibits cell pro-
liferation and induces apoptosis [120]. Interestingly, the accu-
mulation of dihydroceramides was implicated in gammaT-
induced apoptosis [120]. Although dihydroceramides are
thought to be inert or biologically inactive molecules, gammaT
data suggest that they, too – at least when generated in cells –
might be important in the regulation of cancer cell growth
and/or survival. Collectively, these data may suggest that regu-
lation of dihydroceramide generation, via the action of CerS
and/or dihydroceramide desaturase (DES) (Figs. 1 and 2),
might also have important roles in controlling the growth
and/or proliferation of cancer cells. This possibility, however,
warrants further study.
As mentioned above, ceramide generation can be altered by
the regulation of its biochemical synthesis and further metab-
olism. For example, sphingosine, a product of ceramide hydro-
lysis (Fig. 1), causes a massive Golgi fragmentation, and peri-
nuclear vacuolization in HeLa cells [121]. Therefore, under-
standing pathways that are involved in ceramide/sphingosine
metabolism and traﬃcking [122,123] is extremely important
for cancer research and therapy. Thus, the roles for generation
of endogenous ceramide in response to exogenous ceramide or
sphingosine via sphingosine-recycling pathway [124] in the reg-
ulation of telomerase and c-Myc functions [124,125] have been
demonstrated. Recently, another novel biochemical pathway
for the generation of ceramide in the plasma membrane from
ganglioside GM3 by detachment of sugar units in human
ﬁbroblasts has been reported [126]. This pathway, in fact,
may also contribute to the regulation of ceramide levels in can-
cer pathogenesis and therapy, and should be investigated.
Small molecule mimetics of ceramide and inhibitors of
enzymes of ceramide clearance, or generation of S1P, appear
to be promising in inhibiting tumor growth in various animal
models of cancer types. These sphingolipids and their ana-
logues may provide alternative clinical strategies for the treat-
ment of various cancers, and they may have possible functions
in chemoprevention, which is presently best studied in colon
cancer models [119–121,127].
In conclusion, although experimental diﬃculties, inherent in
studying lipid metabolism and function, previously hampered
scientiﬁc progress towards understanding the roles of sphingo-
lipids in cancer pathogenesis and therapy, new lipidomic tech-
nologies [128–132], coupled with proteomics and genomics, are
now available for studying the networks of sphingolipids and
their interacting partners in compartment-speciﬁc pathways
of lipid-regulated functions. Given these developments, we
anticipate signiﬁcant illumination of roles and mechanisms of
action of bioactive lipids, especially sphingolipids in cancer
pathogenesis, therapy, and chemoprevention.
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